91713-26-7

Basic information

• Product Name: methyl 5-(cyanomethyl)-1-(2-deoxy-3,5-di-O-p-toluoyl-α-D-erythro-pentofuranosyl)imidazole-4-carboxylate
• CAS NO: 91713-26-7
• Molecular Weight: 517.538
• Mol File: 91713-26-7.mol

Chemical Properties

• CAS DataBase Reference: methyl 5-(cyanomethyl)-1-(2-deoxy-3,5-di-O-p-toluoyl-α-D-erythro-pentofuranosyl)imidazole-4-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 5-(cyanomethyl)-1-(2-deoxy-3,5-di-O-p-toluoyl-α-D-erythro-pentofuranosyl)imidazole-4-carboxylate(91713-26-7)
• EPA Substance Registry System: methyl 5-(cyanomethyl)-1-(2-deoxy-3,5-di-O-p-toluoyl-α-D-erythro-pentofuranosyl)imidazole-4-carboxylate(91713-26-7)

Safety Data

• Hazardous Substances Data: 91713-26-7(Hazardous Substances Data)

Upstream product

• 3601-89-6 Hoffer's chlorosugar 
• 56039-06-6 methyl 5-(cyanomethyl)-1H-imidazole-4-carboxylate 
• 4330-34-1 methyl 3,5-di-O-toluoyl-2-deoxy-D-ribofuranose 
• 56596-91-9 5-Cyanomethyl-1-trimethylsilanyl-1H-imidazole-4-carboxylic acid methyl ester 

Downstream Products

• 83587-62-6 6-amino-1,5-dihydro-1-(2-deoxy-α-D-erythro-pentofuranosyl)imidazo<4,5-c>pyridin-4-one 
• 91741-79-6 5-(cyanomethyl)-1-(2-deoxy-α-D-erythro-pentofuranosyl)imidazole-4-carboxamide 

Relevant articles and documents

Synthesis and Antiviral/Antitumor Activities of Certain 3-Deazaguanine Nucleosides and Nucleotides

A new procedure for the preparation of the antiviral and antitumor agent 3-deazaguanine (1) and its metabolite 3-deazaguanosine (2) has been developed by reacting methyl 5(4)-(cyanomethyl)imidazole-4(5)-carboxylate (4) and 5-(cyanomethyl)-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)imidazole-4-carboxylate (6), respectively, with hydrazine.The 3-deazaguanosine 3',5'-cyclic phosphate (13) was prepared from 5-(cyanomethyl)-1-β-D-ribofuranosylimidazole-4-carboxamide 5'-phosphate.Glycosylation of the trimethylsilyl 4 with 1-O-methyl-2-deoxy-3,5-di-O-p-toluoyl-D-ribofuranose in the presence of trimethylsilyl trifluoromethanesulfonate gave the corresponding N-1 and N-3 glycosyl derivatives with α-configuration (18 and 20) as the major products, along with minor amounts of the β-anomers (19 and 21).However, glycosylation of the sodium salt of 4 with 1-chloro-2-deoxy-3,5-di-O-p-toluoyl-α-D-erythro-pentofuranose (17) gave exclusively the β-anomers (19 and 21) in good yield.Base-catalyzed ring closure of these imidazole nucleosides gave 2'-deoxy-3-deazaguanosine (29), the α-anomer 28, and the corresponding N-3 positional isomers 27 and 26.The site of glycosylation and the anomeric configuration of these nucleosides have been assigned on the basis of 1H NMR and UV spectral characteristics and by single-crystal X-ray analysis for 27-29.In a preliminary screening, several of these compounds have demonstrated significant broad-spectrum antiviral activity against certain DNA and RNA viruses in vitro, as well as moderate activity against L1210 and P388 leukemia in cell culture.

synthesis and antitumor activity of 2-deoxyribofuranosides of 3-deazaguanine.

Synthesis of 2-deoxyribofuranosides of 3-deazaguanine (IX-XII) has been achieved by a base-catalyzed ring closure of appropriate 2-deoxyribofuranosides of methyl 5(4)-(cyanomethyl)imidazole-4(5)-carboxalate (IV-VII). The separation of isomers and anomers were accomplished by column chromatography and HPLC. The site of glycosidic linkage and the anomeric configurations were established on the basis of C-13 and proton magnetic resonance spectroscopy, as well as UV absorption characteristics. Preliminary results of the antitumor activity of these derivatives, in vitro and in vivo, are described.